Do angiotensin‑II receptor blockers (ARBs) cause hyperkalaemia?

Do ARBs Cause Hyperkalemia?

Yes, angiotensin-II receptor blockers (ARBs) definitively cause hyperkalemia by decreasing renal potassium excretion through inhibition of the renin-angiotensin-aldosterone system. 1

Mechanism and Evidence

ARBs are explicitly listed among drugs that cause hyperkalemia through decreased potassium excretion, alongside ACE inhibitors and mineralocorticoid receptor antagonists. 1 This occurs because blocking angiotensin-II receptors reduces aldosterone secretion, which normally promotes potassium excretion in the distal nephron.

Incidence and Clinical Impact

The risk of hyperkalemia with ARBs varies substantially based on clinical context:

• General hospitalized patients: 0.8-2.1% incidence of hyperkalemia (K+ >5.5 or >6.0 mEq/L) within 15 days of ARB initiation 2
• Real-world unselected populations: Up to 50% incidence when RAASi (including ARBs) are used without stringent monitoring 1
• Heart failure patients: Up to 40% develop hyperkalemia 1
• Advanced chronic kidney disease: Up to 73% develop hyperkalemia 1

The incidence is significantly higher in real-world practice compared to clinical trials (6-12% in trials vs. up to 50% in unmonitored populations), particularly when prescribed to higher-risk patients who did not receive adequate potassium and creatinine monitoring. 1

Risk Factors for ARB-Induced Hyperkalemia

Key risk factors that exponentially increase hyperkalemia risk include:

• Renal impairment: 7.3-fold increased risk at K+ >5.5 mEq/L and 35-fold increased risk at K+ >6.0 mEq/L with elevated baseline creatinine 2
• Chronic kidney disease: 5.7-9.2 times higher incidence 2
• High baseline potassium levels: 6-fold increased risk 3
• Diabetes mellitus 1
• Advanced age 1
• Concomitant medications: NSAIDs, potassium-sparing diuretics, potassium supplements, beta-blockers 1, 3

Timing of Hyperkalemia Onset

Hyperkalemia can occur at any time during ARB therapy, but the highest risk is within the first week:

• 52% of hyperkalemic events occur within the first week of ARB initiation 3
• The highest frequency occurs on the first day after starting ARBs 3
• However, hyperkalemia is distributed throughout the first 15 days without a clear temporal trend 2
• Earlier onset occurs in patients with high baseline potassium, reduced GFR, diabetes, and those without heart failure 3

Critical Clinical Caveat

Life-threatening hyperkalemia can occur even in low-risk patients taking ARBs alone. A 2023 case report documented severe hyperkalemia (9.1 mmol/L) with near-sinusoidal ECG rhythm in a patient whose only risk factor was ARB use—without renal failure, diabetes, adrenal disease, or potassium-sparing diuretics. 4 This demonstrates that while rare, catastrophic hyperkalemia is possible even in seemingly low-risk individuals.

Monitoring Recommendations

Based on multiple guideline organizations, monitoring should follow this algorithm:

Initial monitoring:

• Measure serum potassium and GFR within 1 week of starting ARB therapy 1
• For hospitalized patients, monitor within the first few days, especially if risk factors are present 3

Ongoing monitoring thresholds by guideline:

• KDIGO: Assess GFR and potassium within 1 week of any dose escalation 1
• ESC: Close monitoring required when K+ is 4.5-5.0 mEq/L during up-titration 1

Management Based on Potassium Levels

For K+ 5.0-5.5 mEq/L (mild):

• ARBs are not usually stopped 1
• Use with caution; consider potassium-lowering therapy if increasing 1

For K+ 5.5-6.0 mEq/L (moderate):

• Initiate potassium-lowering therapy if on maximum-tolerated guideline-recommended dose 1
• Continue ARB with close monitoring 1

For K+ >6.0 mEq/L (severe):

• Discontinue or reduce ARB therapy 1
• Reinitiate only after potassium decreases to <5.0 mEq/L and concurrent contributing conditions are controlled 1

For K+ >6.5 mEq/L:

• Discontinue or reduce ARB therapy immediately 1
• Start potassium-lowering therapy 1

Critical Mortality Consideration

Discontinuation of ARBs due to hyperkalemia is associated with significantly worse outcomes. Stopping RAASi therapy is linked to 37% worse survival probability in hospitalized patients. 5 This creates a clinical dilemma: ARBs cause hyperkalemia, but stopping them increases mortality. The solution is aggressive hyperkalemia management to maintain ARB therapy rather than discontinuation.

Practical Approach to Maintain ARB Therapy

When hyperkalemia develops on ARBs:

1. Identify and eliminate other contributing factors: potassium supplements, salt substitutes, NSAIDs, potassium-sparing diuretics 1
2. Consider newer potassium binders (patiromer or sodium zirconium cyclosilicate) to allow continuation of ARB therapy 1
3. Add loop diuretics to increase renal potassium excretion if appropriate 1
4. Only discontinue ARBs as a last resort given the mortality implications 5

The evidence strongly supports that ARBs cause hyperkalemia through a well-established mechanism, but the mortality benefit of continuing ARBs typically outweighs the hyperkalemia risk when properly monitored and managed.